US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Neurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences Inc (NBIX) ニュース

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NBIX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/22	06 : 35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	06 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	06 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	05 : 57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	05 : 51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	05 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	05 : 05	PR Newswire (US)	Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/18	05 : 32	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/18	05 : 31	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/18	05 : 31	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/17	05 : 55	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/17	05 : 40	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/15	05 : 23	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/15	05 : 23	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/14	21 : 30	PR Newswire (US)	Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/09	22 : 45	PR Newswire (US)	Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/09	21 : 30	PR Newswire (US)	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/09	05 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/08	21 : 30	PR Newswire (US)	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/08	05 : 15	PR Newswire (US)	Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/07	21 : 30	PR Newswire (US)	Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/06	21 : 30	PR Newswire (US)	Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/04	02 : 15	PR Newswire (US)	Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/01	20 : 00	PR Newswire (US)	Neurocrine Biosciences Reports First Quarter 2024 Financial Results	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/01	06 : 12	PR Newswire (US)	Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/04/24	21 : 30	PR Newswire (US)	Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/04/23	20 : 00	PR Newswire (US)	Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/04/17	05 : 01	GlobeNewswire Inc.	Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/04/11	05 : 01	PR Newswire (US)	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results	NASDAQ:NBIX	Neurocrine Biosciences Inc

Showing the most relevant articles for your search:NASDAQ:NBIX

1 2 3 4 5 6 7 8 9 10 次へ >>

TMT Acquisition

Viking Line Abp

ANI Pharmaceuticals

Exchange Traded

Lindex Group Oyj

CryptoCricketClub

NeoTerrex Minerals

OReilly Automotive

Oat Tf 0% Fb26 Eur

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約